SG10201705787VA - BISPECIFIC IgG ANTIBODIES AS T CELL ENGAGERS - Google Patents

BISPECIFIC IgG ANTIBODIES AS T CELL ENGAGERS

Info

Publication number
SG10201705787VA
SG10201705787VA SG10201705787VA SG10201705787VA SG10201705787VA SG 10201705787V A SG10201705787V A SG 10201705787VA SG 10201705787V A SG10201705787V A SG 10201705787VA SG 10201705787V A SG10201705787V A SG 10201705787VA SG 10201705787V A SG10201705787V A SG 10201705787VA
Authority
SG
Singapore
Prior art keywords
igg antibodies
bispecific igg
cell engagers
engagers
cell
Prior art date
Application number
SG10201705787VA
Inventor
Alexander Berthold Hendrik Bakker
Loo Pieter Fokko Van
Ton Logtenberg
Original Assignee
Merus Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus Nv filed Critical Merus Nv
Publication of SG10201705787VA publication Critical patent/SG10201705787VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG10201705787VA 2012-09-27 2013-09-27 BISPECIFIC IgG ANTIBODIES AS T CELL ENGAGERS SG10201705787VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261706543P 2012-09-27 2012-09-27
US201361834915P 2013-06-14 2013-06-14

Publications (1)

Publication Number Publication Date
SG10201705787VA true SG10201705787VA (en) 2017-08-30

Family

ID=49382559

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201502451QA SG11201502451QA (en) 2012-09-27 2013-09-27 BISPECIFIC IgG ANTIBODIES AS T CELL ENGAGERS
SG10201705787VA SG10201705787VA (en) 2012-09-27 2013-09-27 BISPECIFIC IgG ANTIBODIES AS T CELL ENGAGERS

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201502451QA SG11201502451QA (en) 2012-09-27 2013-09-27 BISPECIFIC IgG ANTIBODIES AS T CELL ENGAGERS

Country Status (27)

Country Link
US (2) US10358492B2 (en)
EP (2) EP2900694B1 (en)
JP (2) JP6471095B2 (en)
KR (1) KR102390177B1 (en)
CN (2) CN110066338B (en)
AU (2) AU2013324527B9 (en)
BR (1) BR112015006824A2 (en)
CA (1) CA2889681C (en)
CY (1) CY1120976T1 (en)
DK (1) DK2900694T3 (en)
EA (1) EA201590640A1 (en)
ES (1) ES2692951T3 (en)
HK (1) HK1211966A1 (en)
HR (1) HRP20181717T1 (en)
HU (1) HUE042040T2 (en)
IL (1) IL237945B (en)
LT (1) LT2900694T (en)
MX (1) MX2015003885A (en)
NZ (1) NZ630563A (en)
PL (1) PL2900694T3 (en)
PT (1) PT2900694T (en)
RS (1) RS57910B1 (en)
SG (2) SG11201502451QA (en)
SI (1) SI2900694T1 (en)
TR (1) TR201815768T4 (en)
WO (1) WO2014051433A1 (en)
ZA (1) ZA201502835B (en)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
AU2003250074B2 (en) 2002-07-18 2010-09-09 Merus N.V. Recombinant production of mixtures of antibodies
DK3050963T3 (en) 2005-03-31 2019-12-09 Chugai Pharmaceutical Co Ltd Process for producing polypeptide by arrangement control
EP2006381B1 (en) 2006-03-31 2016-02-03 Chugai Seiyaku Kabushiki Kaisha Method for controlling blood pharmacokinetics of antibodies
SG174053A1 (en) 2006-09-01 2011-09-29 Therapeutic Human Polyclonals Inc Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
EP3689912A1 (en) 2007-09-26 2020-08-05 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
EP2647707B1 (en) 2010-11-30 2018-09-12 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
SI2838918T1 (en) 2012-04-20 2019-11-29 Merus Nv Methods and means for the production of heterodimeric ig-like molecules
US10358492B2 (en) 2012-09-27 2019-07-23 Merus N.V. Bispecific IgG antibodies as T cell engagers
TWI682941B (en) 2013-02-01 2020-01-21 美商再生元醫藥公司 Antibodies comprising chimeric constant domains
EP2970505A4 (en) 2013-03-14 2016-10-19 California Inst Biomedical Res Bispecific antibodies and uses thereof
EP3016983B1 (en) * 2013-07-04 2018-05-16 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. A new fusion protein to target and treat acute myloid leukemia cells
WO2015046467A1 (en) 2013-09-27 2015-04-02 中外製薬株式会社 Method for producing polypeptide heteromultimer
EP3110849B9 (en) 2014-02-28 2021-04-07 Merus N.V. Antibody that binds erbb-2 and erbb-3
AU2015223566B2 (en) 2014-02-28 2020-10-08 Merus N.V. Antibodies that bind EGFR and ErbB3
TWI754319B (en) 2014-03-19 2022-02-01 美商再生元醫藥公司 Methods and antibody compositions for tumor treatment
RU2741120C2 (en) 2014-07-21 2021-01-22 Новартис Аг Treating cancer using a chimeric antigenic cll-1 receptor
BR112017004802A2 (en) 2014-09-12 2017-12-12 Genentech Inc anti-cll-1 and immunoconjugate antibodies
MA40764A (en) * 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd THERAPEUTIC AGENT INDUCING CYTOTOXICITY
LT3221359T (en) 2014-11-17 2020-07-27 Regeneron Pharmaceuticals, Inc. Methods for tumor treatment using cd3xcd20 bispecific antibody
LT3221357T (en) * 2014-11-20 2020-08-25 F. Hoffmann-La Roche Ag Common light chains and methods of use
ES2835823T3 (en) 2014-11-20 2021-06-23 Hoffmann La Roche Combination of T-cell activating bispecific antigen-binding molecules for CD3 and folate receptor 1 (FolR1) and PD-1 axis-binding antagonists
CA2976446A1 (en) * 2015-02-13 2016-08-18 Sorrento Therapeutics, Inc. Antibody therapeutics that bind ctla4
MX2017011329A (en) * 2015-03-04 2018-06-06 Sorrento Therapeutics Inc Antibody therapeutics that bind cd47.
DK3277725T3 (en) 2015-03-30 2021-01-11 Regeneron Pharma Constant heavy chain regions with reduced binding to FC gamma receptors
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
WO2016205200A1 (en) * 2015-06-16 2016-12-22 Genentech, Inc. Anti-cll-1 antibodies and methods of use
DK3115376T3 (en) 2015-07-10 2018-11-26 Merus Nv HUMANT CD3 BINDING ANTIBODY
SI3353212T1 (en) * 2015-09-23 2022-01-31 Regeneron Pharmaceuticals, Inc., Optimized anti-cd3 bispecific antibodies and uses thereof
HUE055222T2 (en) 2015-10-23 2021-11-29 Merus Nv Binding molecules that inhibit cancer growth
SG10202006332PA (en) * 2015-10-29 2020-08-28 Hoffmann La Roche Transgenic rabbit with common light chain
WO2017125897A1 (en) 2016-01-21 2017-07-27 Novartis Ag Multispecific molecules targeting cll-1
TW202214700A (en) 2016-03-14 2022-04-16 日商中外製藥股份有限公司 Cell injury inducing therapeutic drug for use in cancer therapy
US20170349660A1 (en) * 2016-06-01 2017-12-07 Xencor. Inc. Bispecific antibodies that bind cd123 and cd3
US20190307799A1 (en) 2016-09-23 2019-10-10 The Regents Of The University Of Michigan Engineered lymphocytes
CA3221995C (en) 2017-02-08 2024-05-28 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
SG11201907648XA (en) * 2017-02-20 2019-09-27 Dragonfly Therapeutics Inc Proteins binding gd2, nkg2d and cd16
CA3054079A1 (en) * 2017-02-20 2018-08-23 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
EP3600413A1 (en) 2017-03-31 2020-02-05 Merus N.V. Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene
CN111278455A (en) * 2017-05-23 2020-06-12 蜻蜓疗法股份有限公司 Proteins that bind NKG2D, CD16 and tumor-associated antigens
US20200157226A1 (en) * 2017-05-23 2020-05-21 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and a tumor-associated antigen
CN111094347B (en) * 2017-07-06 2024-09-20 美勒斯公司 Binding molecules that modulate biological activity expressed by cells
NZ760655A (en) * 2017-07-06 2024-07-05 Merus Nv Antibodies that modulate a biological activity expressed by a cell
EP3649155A1 (en) 2017-07-06 2020-05-13 Merus N.V. Bispecific anti pd1-anti tim3 antibodies
CN118562014A (en) 2017-08-09 2024-08-30 美勒斯公司 Antibodies that bind EGFR and cMET
BR112020005078A2 (en) * 2017-09-14 2020-10-13 Dragonfly Therapeutics, Inc. nkg2d binding proteins, cd16, and type c lecithin-like molecule 1 (cll-1)
EP3693013A4 (en) 2017-10-06 2021-06-30 Ono Pharmaceutical Co., Ltd. Bispecific antibody
US11161911B2 (en) 2017-10-23 2021-11-02 Go Therapeutics, Inc. Anti-glyco-MUC1 antibodies and their uses
WO2019108065A1 (en) 2017-12-01 2019-06-06 Merus N.V. Use of bispecific antibody and il-15 for combination therapy
CA3237846A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the nkg2d receptor
TWI849895B (en) * 2018-02-09 2024-07-21 日商小野藥品工業股份有限公司 Bispecific antibody
US11952424B2 (en) * 2018-03-30 2024-04-09 Merus N.V. Multivalent antibody
TW202016139A (en) 2018-06-13 2020-05-01 瑞士商諾華公司 Bcma chimeric antigen receptors and uses thereof
AU2019288471A1 (en) * 2018-06-22 2021-01-14 Cugene Inc. Novel interleukin-15 (1L-15) fusion proteins and uses thereof
US11590223B2 (en) 2018-08-31 2023-02-28 Regeneron Pharmaceuticals, Inc. Dosing strategy that mitigates cytokine release syndrome for therapeutic antibodies
US20210388093A1 (en) * 2018-10-19 2021-12-16 Regents Of The University Of Minnesota Nk engager molecules and methods of use thereof
WO2020086328A1 (en) * 2018-10-25 2020-04-30 The Medical College Of Wisconsin, Inc. Targeting clptm1l for treatment and prevention of cancer
CN113366018A (en) * 2018-12-20 2021-09-07 美勒斯公司 CLEC12AxCD3 bispecific antibodies and methods for treating disease
EA202191242A1 (en) 2018-12-31 2021-11-25 Мерус Н.В. TRUNKED POLYVALENT MULTIMERS
TW202039578A (en) 2019-03-29 2020-11-01 荷蘭商美勒斯公司 Cd3 binding molecules
TW202102544A (en) 2019-04-04 2021-01-16 日商小野藥品工業股份有限公司 Bispecific antibody
AU2020267349A1 (en) 2019-05-04 2021-11-11 Inhibrx Biosciences, Inc. CLEC12a-binding polypeptides and uses thereof
WO2021006199A1 (en) 2019-07-05 2021-01-14 小野薬品工業株式会社 Treatment of hematologic cancer with pd-1/cd3 dual specificity protein
US20220281977A1 (en) 2019-07-30 2022-09-08 Ono Pharmaceutical Co., Ltd. Bispecific antibody
EP4011918A4 (en) 2019-08-08 2023-08-23 ONO Pharmaceutical Co., Ltd. Dual-specific protein
CN114929745A (en) * 2019-10-17 2022-08-19 明尼苏达大学董事会 CLEC12A antibody fragment sequences and methods
CA3165605A1 (en) 2019-12-24 2021-07-01 Merus N.V. Tgf-beta-rii binding proteins
KR20230008157A (en) * 2020-05-06 2023-01-13 드래곤플라이 쎄라퓨틱스, 인크. Antibodies targeting CLEC12A and their uses
WO2022031935A1 (en) 2020-08-05 2022-02-10 Dragonfly Therapeutics, Inc. Antibodies targeting egfr and use thereof
JP2024516645A (en) * 2021-04-26 2024-04-16 ミレニアム ファーマシューティカルズ， インコーポレイテッド Anti-CLEC12A antibodies and uses thereof
KR20240035504A (en) * 2021-07-20 2024-03-15 에이비엘바이오 주식회사 Anti-CLL-1 antibodies and uses thereof
WO2023107954A1 (en) 2021-12-08 2023-06-15 Dragonfly Therapeutics, Inc. Antibodies targeting 5t4 and uses thereof
GB202214132D0 (en) * 2022-09-27 2022-11-09 Coding Bio Ltd CLL1 binding molecules

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4801687A (en) 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
NZ226694A (en) 1987-10-28 1994-04-27 Oncogen Human immunoglobulin produced by recombinant dna techniques
US5151504A (en) 1989-11-17 1992-09-29 E. R. Squibb & Sons, Inc. Method for purification of monoclonal antibodies
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
JP3502093B2 (en) 1991-07-15 2004-03-02 ザ・ウエルカム・ファウンデーション・リミテッド Production of antibodies
US5457035A (en) * 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
DK0979281T3 (en) * 1997-05-02 2005-11-21 Genentech Inc Process for the preparation of multispecific antibodies with heteromultimers and common components
SI1533380T1 (en) 1999-04-15 2010-03-31 Crucell Holland Bv Recombinant protein production in a human cell comprising at least one E1 protein of adenovirus
AU2002314629B2 (en) 2001-07-04 2007-08-30 Chromagenics B.V. Method of selecting DNA sequence with transcription modulating activity using a vector comprising an element with a gene transcription repressing activity
WO2003107218A1 (en) 2002-05-31 2003-12-24 セレスター・レキシコ・サイエンシズ株式会社 Interaction predicting device
AU2003250074B2 (en) * 2002-07-18 2010-09-09 Merus N.V. Recombinant production of mixtures of antibodies
CN1878795A (en) * 2002-12-02 2006-12-13 阿布格尼克斯公司 Antibodies directed to phospholipase A2 and uses thereof
DE602004002275T2 (en) 2003-01-07 2007-09-06 Symphogen A/S PROCESS FOR PRODUCING RECOMBINANT POLYCLONAL PROTEINS
US20100069614A1 (en) * 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
CA2526284C (en) * 2003-06-25 2014-11-18 Crucell Holland B.V. Binding molecules for the treatment of myeloid cell malignancies
UA94211C2 (en) * 2004-06-03 2011-04-26 Новиммюн С.А. Isolated fully human monoclonal anti-cd3 antibody
SG10201606980VA (en) * 2004-06-03 2016-10-28 Novimmune Sa Anti-cd3 antibodies and methods of use thereof
SE527196C2 (en) 2004-07-08 2006-01-17 Chemel Ab SIRE flow-through detector
EP1789446A2 (en) 2004-09-02 2007-05-30 Genentech, Inc. Heteromultimeric molecules
US20060171929A1 (en) 2005-01-31 2006-08-03 The University Of Washington Regulation of dendritic cell functions by the DCAL-2 receptor
JP2008537941A (en) * 2005-03-31 2008-10-02 ゼンコー・インコーポレイテッド Fc variants with optimized properties
AU2006230413B8 (en) 2005-03-31 2011-01-20 Xencor, Inc Fc variants with optimized properties
DK3050963T3 (en) 2005-03-31 2019-12-09 Chugai Pharmaceutical Co Ltd Process for producing polypeptide by arrangement control
GB2429517B (en) 2005-07-15 2010-10-06 Viridian Concepts Ltd Solar collector devices
BRPI0615745A2 (en) 2005-09-12 2011-05-24 Novimmune Sa anti-cd3 antibody formulation
US20070198410A1 (en) 2005-10-18 2007-08-23 Labgold Marc R Credit fraud prevention systems and methods
PT1999154E (en) 2006-03-24 2013-01-24 Merck Patent Gmbh Engineered heterodimeric protein domains
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
US10118970B2 (en) 2006-08-30 2018-11-06 Genentech, Inc. Multispecific antibodies
US8290739B2 (en) 2006-10-20 2012-10-16 Amfit, Inc. Method for determining relative mobility of regions of an object
WO2008119353A1 (en) 2007-03-29 2008-10-09 Genmab A/S Bispecific antibodies and methods for production thereof
MX2010001684A (en) 2007-08-15 2010-04-21 Amunix Inc Compositions and methods for modifying properties of biologically active polypeptides.
EP2211903A4 (en) * 2007-10-17 2011-07-06 Nuvelo Inc Antibodes to cll-1
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
WO2009089004A1 (en) 2008-01-07 2009-07-16 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
EP2245571B1 (en) 2008-02-05 2019-04-10 Zymeworks Inc. Methods for determining correlated residues in a protein or other biopolymer using molecular dynamics
CA2729095C (en) 2008-06-27 2018-12-04 Merus B.V. Method for producing a transgenic murine mammal
EP2389392A1 (en) 2009-01-26 2011-11-30 Genmab A/S Methods for producing mixtures of antibodies
KR20150036824A (en) 2009-03-20 2015-04-07 제넨테크, 인크. Bispecific anti-her antibodies
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
PL2975051T3 (en) * 2009-06-26 2021-09-20 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
PL2505654T5 (en) * 2010-02-08 2020-11-30 Regeneron Pharmaceuticals, Inc. Common light chain mouse
EP2569337A1 (en) * 2010-05-14 2013-03-20 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
CA2808154A1 (en) * 2010-08-13 2012-02-16 Medimmmune Limited Monomeric polypeptides comprising variant fc regions and methods of use
DK2606064T3 (en) 2010-08-16 2015-04-20 Novimmune Sa Methods for generating multispecific and multivalent antibodies
PT2635607T (en) 2010-11-05 2019-12-11 Zymeworks Inc Stable heterodimeric antibody design with mutations in the fc domain
CN107840894A (en) 2011-03-25 2018-03-27 格兰马克药品股份有限公司 Heterodimer immunoglobulin
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
SI2838918T1 (en) 2012-04-20 2019-11-29 Merus Nv Methods and means for the production of heterodimeric ig-like molecules
US10358492B2 (en) 2012-09-27 2019-07-23 Merus N.V. Bispecific IgG antibodies as T cell engagers
EP3110849B9 (en) 2014-02-28 2021-04-07 Merus N.V. Antibody that binds erbb-2 and erbb-3
AU2015223566B2 (en) 2014-02-28 2020-10-08 Merus N.V. Antibodies that bind EGFR and ErbB3
DK3115376T3 (en) 2015-07-10 2018-11-26 Merus Nv HUMANT CD3 BINDING ANTIBODY

Also Published As

Publication number Publication date
LT2900694T (en) 2018-11-12
PT2900694T (en) 2018-11-13
AU2013324527B9 (en) 2018-07-26
US10358492B2 (en) 2019-07-23
CN105051066A (en) 2015-11-11
BR112015006824A2 (en) 2017-07-04
EP2900694B1 (en) 2018-09-12
CN110066338A (en) 2019-07-30
KR20150076178A (en) 2015-07-06
JP2019068803A (en) 2019-05-09
CN110066338B (en) 2024-04-09
SG11201502451QA (en) 2015-05-28
CA2889681C (en) 2023-04-11
PL2900694T3 (en) 2018-12-31
TR201815768T4 (en) 2018-11-21
MX2015003885A (en) 2015-07-06
EP2900694A1 (en) 2015-08-05
IL237945A0 (en) 2015-05-31
US20190352393A1 (en) 2019-11-21
CA2889681A1 (en) 2014-04-03
US20140120096A1 (en) 2014-05-01
HUE042040T2 (en) 2019-06-28
AU2018204173B2 (en) 2020-05-07
IL237945B (en) 2022-04-01
RS57910B1 (en) 2019-01-31
EA201590640A1 (en) 2015-11-30
KR102390177B1 (en) 2022-04-26
AU2018204173A1 (en) 2018-06-28
JP6471095B2 (en) 2019-02-20
DK2900694T3 (en) 2018-11-19
US12060418B2 (en) 2024-08-13
SI2900694T1 (en) 2018-12-31
ES2692951T3 (en) 2018-12-05
AU2013324527A1 (en) 2015-05-14
CY1120976T1 (en) 2020-05-29
EP3470431A1 (en) 2019-04-17
HK1211966A1 (en) 2016-06-03
ZA201502835B (en) 2016-01-27
JP2015532278A (en) 2015-11-09
CN105051066B (en) 2019-08-06
HRP20181717T1 (en) 2018-12-28
NZ630563A (en) 2017-04-28
AU2013324527B2 (en) 2018-05-24
WO2014051433A1 (en) 2014-04-03

Similar Documents

Publication Publication Date Title
HRP20181717T1 (en) Bispecific igg antibodies as t cell engagers
HUS2400016I1 (en) Anti-fcrn antibodies
HK1217958A1 (en) Tetravalent bispecific antibodies
HK1210620A1 (en) Multi-specific monoclonal antibodies
EP2922874A4 (en) Bispecific antibody
HK1202563A1 (en) Sequence symmetric modified igg4 bispecific antibodies igg4
HK1209137A1 (en) Humanized tau antibody tau
PT2825559T (en) Readily isolated bispecific antibodies with native immunoglobulin format
HK1202565A1 (en) Sequence symmetric modified igg4 bispecific antibodies igg4
HK1204571A1 (en) Protease-regulated antibodies
ZA201506568B (en) Anti-tnf-anti-il-17 bispecific antibodies
HK1210192A1 (en) Anti-siglec-15 antibodies siglec-15
ZA201407272B (en) Anti-baff-anti-il-17 bispecific antibodies
HK1210186A1 (en) Anti-h7cr antibodies h7cr
HK1202454A1 (en) Anti-p-selectin antibody formulation -p-